Form S-8 CRISPR Therapeutics AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
August 6, 2024 6:43 AM EDTRBC Capital analyst Luca Issi lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $60.00 (from $66.00) while maintaining a Sector Perform rating.
The analyst comments "Casgevys launch is under way with >35 ATCs activated (vs >25 last Q) and cells collected from 20... More
